Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Indication Identification Study of LY2523355 in Patients With Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

NCT01059643 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01059643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01059643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Indication Identification Study of LY2523355 in Patients With Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2011
Completion date
December 31, 2012
Enrollment
103 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of head and neck, colorectal cancer, esophageal cancer, gastric cancer, non small cell lung cancer, ovarian cancer, prostate cancer